Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349596 · ClinicalTrials.gov registry record · Phase 1
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
A Phase 1 study of Acute Lymphocytic Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00349596: Completed Phase 1 study of Acute Lymphocytic Leukemia, sponsored by M.D. Anderson Cancer Center.
NCT00349596 is a Phase 1 study of Acute Lymphocytic Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 127-participant average among 24 other Acute Lymphocytic Leukemia trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349596, a Phase 1 study of Acute Lymphocytic Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find the safety of decitabine in patients with acute lymphocytic leukemia. Upon agreement of the patient, additional blood and bone marrow samples to be used to evaluate the effect of the treatment on leukemic cells. Also, with agreement of the patient, any leftover blood and bone marrow samples that are collected at the start of the study and during the regularly scheduled evaluations to be sent for research studies. The research studies will examine changes in the blood and bone marrow cells that might help explain the causes of leukemia.
Conditions Studied
Interventions
- DRUG Decitabine
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-07 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
What the finished NCT00349596 record still lists
NCT00349596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 127-participant average among 24 other Acute Lymphocytic Leukemia trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Acute Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Decitabine is the first listed.
NCT00349596 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00349596 about?
NCT00349596 is a clinical study titled "A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)". The goal of this clinical research study is to find the safety of decitabine in patients with acute lymphocytic leukemia. Upon agreement of the patient, additional blood and bone marrow samples to be used to evaluate the effect of the treatment on leukemic cells. Also, with agreement of the patient,...
What is the current status of trial NCT00349596?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-07. Estimated completion is 2014-10.
What conditions does trial NCT00349596 study?
This clinical trial studies the following conditions: Acute Lymphocytic Leukemia.
What interventions are being tested in trial NCT00349596?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT00349596?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349596 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00349596's enrollment target sits among peer trials
40 12th of 24 higher than 11 of 24 other Acute Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Pilot Imaging Study of Leukemia
RECRUITING · Phase 1
-
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
RECRUITING · Phase 1
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RECRUITING · Phase 1
-
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia